BML-210
BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC50 of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice[1][2][3].
Product Specifications
CAS Number
537034-17-6
UNSPSC
12352005
Hazard Statement
H302, H361, H372, H410
Target
Apoptosis; HDAC
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BML-210.html
Concentration
10mM
Purity
98.04
Solubility
DMSO : ≥ 30 mg/mL
Smiles
O=C(NC1=CC=CC=C1N)CCCCCCC(NC2=CC=CC=C2)=O
Molecular Formula
C20H25N3O2
Molecular Weight
339.43
Precautions
H302, H361, H372, H410
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MAL2 (NM_052886) Human Tagged ORF Clone Lentiviral Particle
Rabbit anti-Saccharomyces cerevisiae (strain 204508/S288c)(Baker's yeast) APM3 Polyclonal Antibody
